Somatic symptoms like fatigue, sleep disturbance, and appetite changes are common in physically ill older adults independent of depression. The original GDS developers deliberately excluded somatic items to improve the specificity of depression screening in medically ill and frail older populations. GDS-5 inherits this property.

GDS-5 can be administered to patients with mild to moderate dementia who retain sufficient comprehension and verbal response ability. In moderate to severe dementia, response reliability decreases—consider observer-rated scales like the Cornell Scale for Depression in Dementia (CSDD) for more advanced cognitive impairment.

GDS-15 has better overall diagnostic accuracy than GDS-5 due to its larger item set and broader symptom coverage. GDS-5 trades specificity for speed—it is most useful as a rapid screening gate. Patients screening positive on GDS-5 should typically proceed to GDS-15 or structured clinical assessment for confirmation.

At a threshold of 2 or above, GDS-5 specificity is approximately 85%, meaning about 15% of positive screens will be false positives. This is acceptable for a screening tool where sensitivity is prioritized. All positive screens require clinical follow-up to distinguish true depression from false positives.

No. GDS-5 is a screening tool only. Prescribing antidepressants should be based on comprehensive clinical assessment including structured diagnostic criteria (DSM-5 or ICD-11), severity assessment, functional impact, medication review, medical cause exclusion, and patient preferences—not on a screening score alone.